HomeRGLS • NASDAQ
Follow
Regulus Therapeutics Inc
Previous close
$2.88
Day range
$2.80 - $2.93
Year range
$0.78 - $3.79
Market cap
188.54M USD
Avg Volume
6.41M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD) | Sep 2023info | Y/Y change |
---|---|---|
Revenue | — | — |
Operating expense | 2.64M | 17.04% |
Net income | -7.82M | -3.62% |
Net profit margin | — | — |
Earnings per share | -0.40 | 20.00% |
EBITDA | -8.07M | -7.14% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Sep 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 30.78M | -32.08% |
Total assets | 37.75M | -27.59% |
Total liabilities | 9.49M | -23.83% |
Total equity | 28.26M | — |
Shares outstanding | 20.22M | — |
Price to book | 2.06 | — |
Return on assets | -49.91% | — |
Return on capital | -55.92% | — |
Cash Flow
Net change in cash
(USD) | Sep 2023info | Y/Y change |
---|---|---|
Net income | -7.82M | -3.62% |
Cash from operations | -6.28M | 6.77% |
Cash from investing | -5.44M | 57.70% |
Cash from financing | 287.00K | -93.61% |
Net change in cash | -11.43M | 24.33% |
Free cash flow | -2.78M | 0.23% |
About
Regulus Therapeutics Inc. or Regulus is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. Wikipedia
Founded
Sep 2007
Website
Employees
30